KospicyKorean filings in English
Filings / Kwangdong Pharmaceutical

Preliminary Consolidated Operating Results (Fair Disclosure)

Kwangdong Pharmaceutical · 연결재무제표기준영업(잠정)실적(공정공시)

8-KKOSPI · 009290 Filed 2026-11-11Korean original on DART

English form view 72% translated

Translated from a fixed dictionaryLeft in Korean (free text, names)Numbers and dates are copied unchanged

Preliminary consolidated operating results (Fair Disclosure)

Results Period
Current Period Results2026-07-01~2026-09-30
Prior Period Results2026-04-01~2026-06-30
Prior-Year Same Period Results2025-07-01~2025-09-30
Current Period Cumulative Results2026-01-01~2026-09-30
Prior-Year Same Period Cumulative Results2025-01-01~2025-09-30
※ Preliminary figures; subject to change upon finalization.
1. Consolidated resultsUnit: KRW m, %
CategoryCurrent Period ResultsPrior Period Resultsvs. Prior PeriodPrior-Year Same Period ResultsYoY
(2026.3Q)(2026.2Q)Change (%)Profit/loss turnaround(2025.3Q)Change (%)Profit/loss turnaround
RevenueCurrent Results460,613439,8164.7-444,5173.6-
Cumulative Results1,311,283---1,247,4105.1-
Operating IncomeCurrent Results7,0392,823149.4-10,869-35.2-
Cumulative Results17,383---18,718-7.1-
Income from continuing operations before income taxCurrent Results7854,442-82.3-14,320-94.5-
Cumulative Results11,786---23,397-49.6-
Net IncomeCurrent Results6573,164-79.2-11,106-94.1-
Cumulative Results8,721---17,563-50.3-
Net income attributable to owners of the parentCurrent Results1,1532,708-57.4-10,787-89.3-
Cumulative Results8,262---17,042-51.5-
--------
2. Information ProvidedInformation Provider광동제약(주) 자금팀
Information Recipient국내외 정보이용자
Information release date (scheduled)Ad Hoc Provision After Fair Disclosure
Information release time (scheduled)-
Event Name (Venue)-
3. ContactResponsible Department광동제약(주) 자금팀
Phone Number02-6006-7734
4. Other Material Matters Relevant to Investment Decisions
- 상기 내용은 한국채택국제회계기준(K-IFRS)에 따라 작성된 연결기준 잠정영업실적입니다. - 상기 실적은 외부감사인의 검토가 완료되지 않은 자료로, 향후 검토 결과에 따라 변경될 수 있습니다.
※ Related Disclosures2026-10-30 Advance Notice of Annual Results Disclosure (Guidance Disclosure)